Mutations of ASXL1 and TET2 in aplastic anemia.
作者信息
Huang Jinbo, Ge Meili, Lu Shihong, Shi Jun, Li Xingxin, Zhang Jizhou, Wang Min, Yu Wei, Shao Yingqi, Huang Zhendong, Zhang Jing, Nie Neng, Zheng Yizhou
机构信息
State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, P.R. China.
State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, P.R. China
出版信息
Haematologica. 2015 May;100(5):e172-5. doi: 10.3324/haematol.2014.120931. Epub 2015 Jan 16.
Abstract
摘要
相似文献
1
Mutations of ASXL1 and TET2 in aplastic anemia.再生障碍性贫血中ASXL1和TET2的突变
Haematologica. 2015 May;100(5):e172-5. doi: 10.3324/haematol.2014.120931. Epub 2015 Jan 16.
2
Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.体细胞突变可识别出进展为骨髓增生异常综合征的再生障碍性贫血患者亚组。
Blood. 2014 Oct 23;124(17):2698-704. doi: 10.1182/blood-2014-05-574889. Epub 2014 Aug 18.
3
Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.RARS-T 患者的突变谱包括 TET2 和 ASXL1 突变。
Leuk Res. 2010 Aug;34(8):969-73. doi: 10.1016/j.leukres.2010.02.033. Epub 2010 Mar 23.
4
Genetic characterization of acquired aplastic anemia by targeted sequencing.通过靶向测序对获得性再生障碍性贫血进行基因特征分析。
Haematologica. 2014 Sep;99(9):e165-7. doi: 10.3324/haematol.2013.101642. Epub 2014 Jun 6.
5
Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.TET2 和 ASXL1 突变在骨髓增殖性肿瘤发病机制中的作用。
Hematol Oncol Clin North Am. 2012 Oct;26(5):1053-64. doi: 10.1016/j.hoc.2012.07.006. Epub 2012 Aug 21.
6
Mutations and karyotype predict treatment response in myelodysplastic syndromes.基因突变和核型可预测骨髓增生异常综合征的治疗反应。
Am J Hematol. 2018 Nov;93(11):1420-1426. doi: 10.1002/ajh.25267. Epub 2018 Sep 30.
7
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia.慢性髓性白血病中TET2、IDH1、IDH2和ASXL1的突变分析
Leukemia. 2011 Oct;25(10):1661-4. doi: 10.1038/leu.2011.139. Epub 2011 Jun 3.
8
ASXL1 single nucleotide polymorphisms rs62206933, rs117901891, and rs74638057 identify a subgroup of acquired aplastic anemia in Chinese Han patients.ASXL1单核苷酸多态性rs62206933、rs117901891和rs74638057可鉴定中国汉族获得性再生障碍性贫血患者的一个亚组。
Int J Lab Hematol. 2015 Dec;37(6):e163-7. doi: 10.1111/ijlh.12412. Epub 2015 Aug 3.
9
genotype-based risk stratification outperforms mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia.基于基因型的风险分层在慢性粒单核细胞白血病中优于突变影响，且独立于突变变异等位基因分数。
Haematologica. 2024 Oct 1;109(10):3419-3425. doi: 10.3324/haematol.2024.285410.
10
Telomerase mutations in aplastic anemia.再生障碍性贫血中的端粒酶突变
N Engl J Med. 2005 Apr 7;352(14):1481-3. doi: 10.1056/NEJMe058015.
引用本文的文献
1
Hematopoietic stem cell transplantation and immunosuppressive therapy: implications of clonal haematopoiesis.造血干细胞移植与免疫抑制治疗：克隆性造血的影响
Ann Hematol. 2025 Mar;104(3):1877-1886. doi: 10.1007/s00277-024-06152-6. Epub 2025 Jan 28.
2
Clinical implications of myeloid malignancy‑related somatic mutations in aplastic anemia.骨髓增生异常相关体细胞突变在再生障碍性贫血中的临床意义。
Clin Exp Med. 2023 Dec;23(8):4473-4482. doi: 10.1007/s10238-023-01067-4. Epub 2023 Apr 22.
3
Association between human leukocyte antigen and immunosuppressive treatment outcomes in Chinese patients with aplastic anemia.中国人再生障碍性贫血患者人类白细胞抗原与免疫抑制治疗结果的相关性。
Front Immunol. 2023 Jan 30;14:1056381. doi: 10.3389/fimmu.2023.1056381. eCollection 2023.
4
Somatic mutations in aplastic anemia: Significance for classification, therapy, and outcome.再生障碍性贫血中的体细胞突变：对分类、治疗及预后的意义。
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000212. eCollection 2019 Jun.
5
Hypoplastic myelodysplastic syndrome and acquired aplastic anemia: Immune‑mediated bone marrow failure syndromes (Review).发育不全性骨髓增生异常综合征和获得性再生障碍性贫血：免疫介导的骨髓衰竭综合征（综述）。
Int J Oncol. 2022 Jan;60(1). doi: 10.3892/ijo.2021.5297. Epub 2021 Dec 27.
6
Approach to the diagnosis of aplastic anemia.再生障碍性贫血的诊断方法。
Blood Adv. 2021 Jun 22;5(12):2660-2671. doi: 10.1182/bloodadvances.2021004345.
7
BCOR gene alterations in hematologic diseases.BCOR 基因改变与血液系统疾病。
Blood. 2021 Dec 16;138(24):2455-2468. doi: 10.1182/blood.2021010958.
8
Detectable mutations precede late myeloid neoplasia in aplastic anemia.再生障碍性贫血中可检测到的突变先于晚期骨髓增殖性肿瘤出现。
Haematologica. 2021 Feb 1;106(2):647-650. doi: 10.3324/haematol.2020.263046.
9
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.获得性再生障碍性贫血和阵发性睡眠性血红蛋白尿症中的继发性骨髓增生异常综合征和白血病。
Blood. 2020 Jul 2;136(1):36-49. doi: 10.1182/blood.2019000940.
10
Acquired Aplastic Anemia as a Clonal Disorder of Hematopoietic Stem Cells.获得性再生障碍性贫血作为造血干细胞的克隆性疾病。
Stem Cell Rev Rep. 2020 Jun;16(3):472-481. doi: 10.1007/s12015-020-09971-y.
本文引用的文献
1
Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.体细胞突变可识别出进展为骨髓增生异常综合征的再生障碍性贫血患者亚组。
Blood. 2014 Oct 23;124(17):2698-704. doi: 10.1182/blood-2014-05-574889. Epub 2014 Aug 18.
2
TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.TET2、ASXL1 和 EZH2 基因突变与中国人骨髓增生异常综合征。
Leuk Res. 2013 Mar;37(3):305-11. doi: 10.1016/j.leukres.2012.10.004. Epub 2012 Oct 23.
3
SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes.基于 SNP 阵列的核型分析：再生障碍性贫血和低细胞性骨髓增生异常综合征的差异和相似之处。
Blood. 2011 Jun 23;117(25):6876-84. doi: 10.1182/blood-2010-11-314393. Epub 2011 Apr 28.
4
Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: a single-center experience.802 例再生障碍性贫血患者克隆演变的长期随访：单中心经验。
Ann Hematol. 2011 May;90(5):529-37. doi: 10.1007/s00277-010-1140-9. Epub 2011 Jan 5.
5
Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML.对269例骨髓增生异常综合征（MDS）或继发性急性髓系白血病（AML）患者进行RUNX1、MLL-PTD、FLT3-ITD、NPM1和NRAS的突变分析。
Leukemia. 2010 Aug;24(8):1528-32. doi: 10.1038/leu.2010.124. Epub 2010 Jun 3.
6
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.骨髓增殖性肿瘤中的新突变及其功能和临床相关性：JAK2、MPL、TET2、ASXL1、CBL、IDH 和 IKZF1。
Leukemia. 2010 Jun;24(6):1128-38. doi: 10.1038/leu.2010.69. Epub 2010 Apr 29.
7
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.多梳蛋白相关基因ASXL1在骨髓增生异常综合征和急性髓系白血病中频繁发生突变。
Leukemia. 2010 May;24(5):1062-5. doi: 10.1038/leu.2010.20. Epub 2010 Feb 25.
8
Aplastic anemia: pathophysiology and treatment.再生障碍性贫血：病理生理学与治疗。
Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S119-25. doi: 10.1016/j.bbmt.2009.09.013. Epub 2009 Sep 24.
9
Guidelines for the diagnosis and management of aplastic anaemia.再生障碍性贫血诊断与治疗指南。
Br J Haematol. 2009 Oct;147(1):43-70. doi: 10.1111/j.1365-2141.2009.07842.x. Epub 2009 Aug 10.
10
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).TET2突变是骨髓增生异常综合征（MDS）中一个独立的有利预后因素。
Blood. 2009 Oct 8;114(15):3285-91. doi: 10.1182/blood-2009-04-215814. Epub 2009 Aug 7.
Zotero 插件